Jessica Ailani
MedStar Georgetown University Hospital · MedStar's Georgetown University Hospital · MedStar Georgetown Headache Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jessica Ailani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:09 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07629635 · Migraine Headaches Elimination With Patent Foramen Ovale-Directed TherapyColumbia University · recruiting · Migraine Disease, Patent Foramen Ovale · principal investigator
- Ph4NCT07301008 · Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the USMedstar Health Research Institute · recruiting · Migraine, Trigger Induced Migraine · principal investigator
- N/ANCT06874361 · Cooling to Alleviate Migraine #3Mi-Helper, Inc. · completed · Migraine With or Without Aura, Migraine, Migraine Headache · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:09 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.JAMA Neurol · 2018408 citationsRCR 22.1
- Ubrogepant for the Treatment of Migraine.N Engl J Med · 2019252 citationsRCR 14.8
- Atogepant for the Preventive Treatment of Migraine.N Engl J Med · 2021234 citationsRCR 18.7
- 203 citationsRCR 12.7
- Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.Lancet Neurol · 2020172 citationsRCR 12.1
- 108 citationsRCR 18.3
- 75 citationsRCR 6.7
- Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.Headache · 202074 citationsRCR 5.6
- 66 citationsRCR 3.7
- 49 citationsRCR 3.2